We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Groupe Crit | EU:CEN | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.20 | -0.27% | 73.80 | 73.80 | 74.00 | 74.00 | 73.80 | 74.00 | 188 | 08:09:26 |
RNS Number:9239Q CeNeS Pharmaceuticals PLC 16 October 2003 CeNeS announces appointment of Dr Peter Johnson as non-executive director Cambridge, UK, 16th October 2003 - CeNeS Pharmaceuticals plc (LSE: CEN) today announced the appointment of Dr Peter Johnson as a non-executive director of CeNeS Pharmaceuticals plc ("CeNeS"). Dr Johnson has had extensive experience at senior executive and non-executive level in a number of major pharmaceutical and biotechnology companies and is currently Chairman of Oxford BioMedica plc and Executive Chairman of Sterix Limited. Commenting on the appointment, Alan Goodman, Chairman of CeNeS said, "I am delighted to welcome Dr Johnson to the CeNeS Board. His extensive experience of big pharma research and development and growing biotechnology companies will be of great value to CeNeS as our development pipeline progresses into late stage clinical development. This appointment is also another step forward for CeNeS as the Company progresses its corporate development. The Board believe that CeNeS is well positioned to deliver value to shareholders in the future." For more information please contact: CeNeS Pharmaceuticals plc Neil Clark Tel: +44 (0)1223 266466 Fax: +44 (0)1223 266467 Notes to Editors: CeNeS is a biopharmaceutical company specialising in the development and commercialisation of drugs for pain control. The company has development assets targeting pain and has a portfolio of carried interests in assets that it has divested. The company is based in Cambridge, England. For further information visit www.cenes.co.uk. Dr Peter Johnson, Ph.D., (67) has extensive R&D experience with five major international pharmaceutical companies: Wellcome, Hoechst, SmithKline, Fisons and Astra. He was formerly Chairman and Managing Director of SmithKline and French Research Ltd and Group Main Board Director of R&D Worldwide for Fisons. Formerly a Director of Proteus Molecular Design and Non-Executive Director and Chairman of the Scientific Advisory Board of Quadrant Healthcare plc, he is currently Chairman of Oxford BioMedica plc and Sterix Limited. Within the last five years he was a non-executive director of Quadrant Healthcare Limited and CBAMS Limited. CeNeS confirms that no other details are required to be disclosed under paragraph (f) of Schedule 2 of the AIM Rules with respect to Dr Johnson. This information is provided by RNS The company news service from the London Stock Exchange END BOAGUGCPUUPWGGA
1 Year Groupe Crit Chart |
1 Month Groupe Crit Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions